The second consecutive guidance raise and accelerating ARCALYST penetration (21% of 14K addressable patients) suggest durable commercial momentum. Watch for KPL-387 Phase 3 enrollment updates and KPL-1161 Phase 1 initiation as pipeline catalysts through 2026.
Price Chart
Executive Summary
Kiniksa reported Q2 2026 ARCALYST net product revenue of $243.6M (~55% YoY growth), beating consensus estimates of $226.5M. The company raised full-year 2026 ARCALYST guidance for the second consecutive quarter to $980-$995M, and announced positive Phase 2 data for KPL-387 with the Phase 3 PASTORALE trial now enrolling. Net income was $25.4M ($0.30 diluted EPS) vs $17.8M a year ago, with cash growing to $525.9M and no debt.
Key Financial Metrics
Key Facts
- ARCALYST Q2 2026 net product revenue of $243.6M, ~55% YoY growth vs $156.8M
- Full-year 2026 ARCALYST guidance raised to $980-$995M from prior $930-$945M
- EPS of $0.30 beat consensus of $0.28 (+5.3% surprise)
- Net income of $25.4M vs $17.8M in Q2 2025
- Cash, cash equivalents, and short-term investments of $525.9M, no debt
- KPL-387 Phase 2 data showed rapid pain/CRP reduction; Phase 3 PASTORALE enrolling
- KPL-1161 on track for Phase 1 initiation by end of 2026
Financial Impact
ARCALYST revenue beat consensus by ~$17M; guidance raised by $50M at midpoint; net income up 43% YoY
Risk Factors
- ARCALYST revenue concentration risk with no other approved products
- KPL-387 Phase 3 trial (PASTORALE) may fail to replicate Phase 2 efficacy
- Rising operating expenses (R&D + SG&A up 58% YoY) could pressure margins if revenue growth slows
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3334131 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $76.73 | awaiting T+60 | — | $72.98 (−4.89%) |
Oct 22, 2026 4d ago | Press Release | $80.79 | awaiting T+60 | — | $72.98 (−9.67%) |
Sep 3, 2026 7w ago | 144 | $77.91 | awaiting T+60 | — | $72.98 (−6.33%) |
Jul 28, 2026 12w ago | 8-K | $79.44 $79.70 | ▲ +0.33% | ▼ −4.02% | $72.98 (−8.13%) |
Jul 28, 2026 12w ago | Press Release | $79.44 $79.70 | ▲ +0.33% | ▼ −4.02% | $72.98 (−8.13%) |
May 26, 2026 21w ago | 8-K | $51.84 $78.47 | ▲ +51.37% | ▲ +49.49% | $72.98 (+40.78%) |
May 1, 2026 25w ago | 8-K | $57.62 $80.92 | ▲ +40.44% | ▲ +38.58% | $72.98 (+26.66%) |
Apr 28, 2026 25w ago | 144 | $52.99 $62.84 | ▼ −18.59% | ▼ −14.48% | $72.98 (−37.72%) |
Apr 28, 2026 25w ago | Press Release | $53.85 $63.05 | ▲ +17.08% | ▲ +13.10% | $72.98 (+35.52%) |
Apr 28, 2026 25w ago | Insider Cluster | $53.85 $63.05 | ▲ +17.08% | ▲ +13.10% | $72.98 (+35.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers